931. Telemedicine for the Treatment of Hepatitis C: A Systematic Review and Meta-Analysis
Session: Oral Abstract Session: Hepatitis C: Epidemiology and Elimination
Friday, October 5, 2018: 9:15 AM
Room: W 2002

Hepatitis C (HCV) is a curable cause of liver disease, typically treated by specialists. Access to specialists is limited in rural areas. Telemedicine between generalists and specialists could yield outcomes comparable to care provided by specialists in face-to-face (FTF) encounters. To assess the effectiveness of HCV treatment through telemedicine compared to usual care, as measured by sustained virologic response (SVR).


We searched MEDLINE, the Cochrane Library, ClinicalTrials.gov, the Database of Abstracts of Reviews of Effects, and Excerpta Medica DataBASE from inception to March 2018. We included Randomized Controlled Trials (RCTs) and cohort studies comparing telemedicine in rural settings to FTF encounters with specialists in treating HCV. Studies reported cure as measured by SVR. We did not apply any exclusion criteria. At least two independent researchers used PRISMA guidelines to extract data. We used a modified Newcastle-Ottawa Scale and the Cochrane Collaboration Tool for Assessing Risk of Bias to assess observational studies and RCTs. We used a random-effects model to calculate pooled odds ratios (OR). The primary outcome was clinical cure. Cure was defined as SVR at 12 weeks after completion of treatment.


Of 1,211 potentially eligible studies, 10 studies, representing 43,117 subjects, met inclusion criteria. Pooled analysis showed no difference in the odds of achieving SVR when comparing telemedicine to FTF specialist care (OR 1.01 [95% CI 0.78-1.30]). This result was robust across sensitivity analyses, including restriction to patients who completed treatment (OR 0.78 [95% CI 0.43-1.43]), exclusion of outliers, and exclusion of abstracts. There was significant heterogeneity [p=0.003, I2=64].


In rural areas with limited access to specialists, care provided by telemedicine-supported generalists is as effective as FTF specialist care in achieving cure of HCV. Telemedicine is a viable option to expand access to HCV care in rural settings.

David De Gijsel, MD, MSc1, Blake Kruger, BS2, Dema Hakim, BS2 and Sarah Moore, BA2, (1)Infectious Disease, Dartmouth-Hitchcock Medical Center, Lebanon, NH, (2)The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH


D. De Gijsel, None

B. Kruger, None

D. Hakim, None

S. Moore, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.